Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Non-Current Debt (2016 - 2017)

Protalix BioTherapeutics has reported Non-Current Debt over the past 6 years, most recently at $4.3 million for Q3 2017.

  • Quarterly results put Non-Current Debt at $4.3 million for Q3 2017, changed 0.0% from a year ago — trailing twelve months through Sep 2017 was $4.3 million (changed 0.0% YoY), and the annual figure for FY2016 was $4.3 million, changed 0.0%.
  • Non-Current Debt for Q3 2017 was $4.3 million at Protalix BioTherapeutics, roughly flat from $4.3 million in the prior quarter.
  • Over the last five years, Non-Current Debt for PLX hit a ceiling of $4.3 million in Q4 2015 and a floor of $376000.0 in Q2 2013.
  • Median Non-Current Debt over the past 4 years was $4.3 million (2015), compared with a mean of $3.6 million.
  • Biggest five-year swings in Non-Current Debt: crashed 91.97% in 2013 and later changed 0.0% in 2016.
  • Protalix BioTherapeutics' Non-Current Debt stood at $2.4 million in 2013, then skyrocketed by 81.4% to $4.3 million in 2015, then changed by 0.0% to $4.3 million in 2016, then changed by 0.0% to $4.3 million in 2017.
  • The last three reported values for Non-Current Debt were $4.3 million (Q3 2017), $4.3 million (Q2 2017), and $4.3 million (Q1 2017) per Business Quant data.